will semaglutide compound be banned Fifth Circuit probes FDA ban on compounded GLP-1s New Novo Nordisk initiatives support

Understanding unraveling the connection between Long COVID and ME/CFS requires deeply acknowledging this shared, underlying mitochondrial pathology

Year in Review: The 10 most-read pharma articles of 2025 We feature the most popular articles published on CPHI Online from 2025, ranging from blockbuster news over GLP-1 therapies, including discussions with experts on the subject, to some of our regular interview series features, and content surrounding our biggest event of the year, CPHI Frankfurt

Rybelsus, the GLP-1 agonist in Pill Form, to Launch in Canadian Market in April 2020 By Frida Velcani Rybelsus, a GLP-1 agonist pill already approved in Europe and the US, has just been approved by Health Canada for adults with type 2 diabetes In Canada, the first and only GLP-1 agonist pill has received approval for people with type 2 diabetes

We offer a medically supervised, affordable, results-driven weight loss program delivered 100% virtually